The Past Week's Notable Insider Buys: Agree Realty, Avis Budget, Zoetis And More

  • Insider buying can be an encouraging signal for potential investors, especially when markets face uncertainty.
  • Returning buyers and chief executives were among the insiders making purchases this week.
  • Biotechs, REITs and a car rental leader saw notable insider purchasing of shares.

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider buying can be an encouraging signal for potential investors, particularly when there is uncertainty in the markets or the markets are near all-time highs.

Here are some of the most noteworthy insider purchases that were reported in the past week.

American Assets Trust, Inc AAT saw its chief executive officer, Ernest Rady, indirectly acquire about 118,000 shares of this San Diego-based real estate investment trust recently. At prices ranging from $29.44 to $30.26 per share, the total for these purchases came to over $5.31 million.

A 10% owner that has been acquiring shares of Austin, Texas-based Molecular Templates Inc MTEM since last October picked up about 309,000 more of them in the past week. The most recent transactions cost that owner more than $3.51 million, at per-share prices ranging from $11.28 to $11.48.

Opko Health Inc. OPK had CEO Phillip Frost, a frequent buyer, return to add to his stake once more. The 500,000 shares acquired via trust most recently, at $4.71 to $4.81 apiece, totaled more than $2.38 million. Unfortunately, the Miami-based company's stock ended the week at $4.50 per share.

One director recently acquired more than 53,600 Sonos Inc SONO shares via family trust. The prices for that ranged from $36.91 to $37.49 per share, and that cost him more than $2 million. Note that this director and other insiders were selling shares of this consumer electronics firm earlier in February.

Before its CEO parted with some shares late last week, a beneficial owner bought more than 10,700 United States Lime & Minerals Inc USLM shares for an average of $139.80 apiece. The total for that owner's purchase was nearly $1.50 million. The stock hit a year-to-date high above $45 last week, before pulling back.

Two Agree Realty Corporation ADC directors stepped up to the buy window this past week. At $62.93 to $64.56 apiece, the more than 19,800 shares acquired altogether added up to over $1.26 million. This retail-focused real estate investment trust had a record-breaking 2020.

Pet health care company Zoetis Inc ZTS saw one director buck the trend at a time when other insiders were selling the shares. The almost 7,600 shares that director acquired via trust, at prices ranging from $163.26 to $165.89 apiece, totaled almost $1.25 million. Alas, the stock ended the week down at $155.24 a share.

A Royalty Pharma plc RPRX director indirectly scooped up some 25,700 of its shares late last week. At prices between $46.42 and $47.09 per share, that cost the director more than $1.2 million. Shares of this New York-based acquirer of biopharmaceutical royalties ended the week trading at $46.57 apiece.

Avis Budget Group Inc. CAR had its chief financial officer pull the trigger during the week as well. The more than 23,700 shares he acquired, at prices between $45.75 and $47.65 per share, added up to around $1.09 million. The stock ended the week trading at $55.55 a share, so a quick 16% or so gain for that buyer.

And Incyte Corporation INCY CEO Herve Hoppenot acquired more than 12,900 of its shares midweek. At an average share price of $77.37, that cost the director about $1 million, and it lifted his stake in the biopharmaceutical company to more than 284,200 shares.

See also: Warren Buffett In Annual Letter Signals More Stock Buybacks Coming This Year, Says Don't 'Bet Against America'

Note that some smaller amount of insider buying at Abbott Laboratories ABT, Cerner Corporation CERN, DuPont de Nemours Inc DD, Ford Motor Company F and Macy's Inc M was reported in the past week as well.

At the time of this writing, the author had no position in the mentioned equities.

Keep up with all the latest breaking news and trading ideas by following Benzinga on Twitter.

Photo by Charles Forerunner on Unsplash.

Posted In: abbott laboratoriesAgree RealtyAmerican Assets TrustAvis BudgetcernerDuPontFordIncytemacy'sMolecular TemplatesOpko HealthRoyalty PharmaSonosU.S. Lime & MineralsZoetisPenny StocksSmall CapMediaTrading Ideas

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.